This retrospective multicentre study provides evidence on the effectiveness and safety of SG in the treatment of metastatic breast cancer (mBC), both in patients with triple-negative breast cancer and in those with HR+/HER2− disease. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.